CA2137377C - Retinal pigmented epithelium derived neurotrophic factor - Google Patents

Retinal pigmented epithelium derived neurotrophic factor Download PDF

Info

Publication number
CA2137377C
CA2137377C CA2137377A CA2137377A CA2137377C CA 2137377 C CA2137377 C CA 2137377C CA 2137377 A CA2137377 A CA 2137377A CA 2137377 A CA2137377 A CA 2137377A CA 2137377 C CA2137377 C CA 2137377C
Authority
CA
Canada
Prior art keywords
pednf
cells
polypeptide
protein fraction
ammonium sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2137377A
Other languages
English (en)
French (fr)
Other versions
CA2137377A1 (en
Inventor
Lincoln V. Johnson
Joyce Tombran-Tink
Gerald J. Chader
Fintan R. Steele
Sofia Patricia Becerra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California
United States Department of Health and Human Services
Original Assignee
University of Southern California
United States Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California, United States Department of Health and Human Services filed Critical University of Southern California
Publication of CA2137377A1 publication Critical patent/CA2137377A1/en
Application granted granted Critical
Publication of CA2137377C publication Critical patent/CA2137377C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
CA2137377A 1992-06-04 1993-06-04 Retinal pigmented epithelium derived neurotrophic factor Expired - Lifetime CA2137377C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89421592A 1992-06-04 1992-06-04
US07/894,215 1992-06-04
PCT/US1993/005358 WO1993024529A1 (en) 1992-06-04 1993-06-04 Retinal pigmented epithelium derived neurotrophic factor

Publications (2)

Publication Number Publication Date
CA2137377A1 CA2137377A1 (en) 1993-12-09
CA2137377C true CA2137377C (en) 2011-03-08

Family

ID=25402767

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2137377A Expired - Lifetime CA2137377C (en) 1992-06-04 1993-06-04 Retinal pigmented epithelium derived neurotrophic factor

Country Status (6)

Country Link
EP (2) EP0662087B1 (enExample)
JP (3) JPH07508646A (enExample)
AU (1) AU4406993A (enExample)
CA (1) CA2137377C (enExample)
DE (1) DE69333229T2 (enExample)
WO (1) WO1993024529A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6319687B1 (en) * 1992-09-24 2001-11-20 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization, genomic organization and sequence of PEDF gene
US6451763B1 (en) 1992-06-04 2002-09-17 The United States Of America As Represented By The Department Of Health And Human Services Retinal pigmented epithelium derived neurotrophic factor and methods of use
US5840686A (en) * 1992-09-24 1998-11-24 The United States Of America As Represented By The Department Of Health And Human Services Pigment epithelium-derived factor: characterization of its novel biological activity and sequences encoding and expressing the protein and methods of use
DK0755446T3 (da) * 1994-04-25 2007-01-29 Genentech Inc Cardiotrophin og anvendelser deraf
US6472585B1 (en) 1994-04-25 2002-10-29 Genentech, Inc. Cardiotrophin-1 defective mouse
US7258983B2 (en) 1994-04-25 2007-08-21 Genentech, Inc. Cardiotrophin-1 compositions and methods for the treatment of tumor
US5534615A (en) * 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5804376A (en) * 1995-05-02 1998-09-08 Incyte Pharmaceuticals, Inc. Pancreas-derived serpin
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US6288024B1 (en) 1997-07-23 2001-09-11 Northwestern University Methods and compositions for inhibiting angiogenesis
US7105496B2 (en) 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6821775B1 (en) 2000-02-11 2004-11-23 Genvec, Inc. Viral vector encoding pigment epithelium-derived factor
EP1265627B1 (en) * 2000-02-23 2008-11-05 Northwestern University Pharmaceutical compositions for inhibiting angiogenesis by pedf fragments
US20030158112A1 (en) 2002-02-15 2003-08-21 Johns Hopkins University School Of Medicine Selective induction of apoptosis to treat ocular disease
US20040166091A1 (en) 2003-02-24 2004-08-26 Genvec, Inc. Materials and methods for treating disorders of the ear
WO2006046584A1 (ja) * 2004-10-26 2006-05-04 Santen Pharmaceutical Co., Ltd. 視細胞障害治療剤
US8173591B2 (en) 2004-11-16 2012-05-08 Yeda Research And Development Co. Variants of pigment epithelium derived factor and uses thereof
WO2006064512A1 (en) * 2004-12-13 2006-06-22 Unichem Laboratories Limited A process of fractionating and storing proteins
EP1951284A4 (en) 2005-11-14 2010-05-05 Yeda Res & Dev IMPROVED VARIANTS OF DERIVED FACTOR OF PIGMENTARY EPITHELIUM AND USES THEREOF
US9938328B2 (en) * 2012-09-17 2018-04-10 Mackay Memorial Hospital Use of PEDF-derived polypeptides for treating alopecia and/or hair depigmentation
TWI710635B (zh) 2014-10-09 2020-11-21 美商珍維克公司 編碼人類無調同源物-1(hath1)之腺病毒載體
JP6522063B2 (ja) * 2017-08-10 2019-05-29 マクカイ メモリアル ホスピタル 脱毛症及び／又は毛髪色素脱失を治療するためのｐｅｄｆ由来のポリペプチドの使用
CN112912491A (zh) * 2018-09-27 2021-06-04 加利福尼亚大学董事会 用于基于细胞的疗法或治疗的测定
EP3705132A1 (en) * 2019-03-04 2020-09-09 Curebiotec GmbH Method for the treatment of a disease using pigment epithelium-derived factor (pedf)
CN114981298B (zh) 2019-12-12 2024-08-20 听治疗有限责任公司 用于预防和治疗听力损失的组合物和方法
EP4330411B1 (en) 2021-04-27 2026-03-18 4D Molecular Therapeutics Inc. Compositions and methods for treatment of ocular disease associated with angiogenesis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5229500A (en) * 1989-08-30 1993-07-20 Regeneron Pharmaceuticals, Inc. Brain derived neurotrophic factor

Also Published As

Publication number Publication date
EP0662087A4 (en) 1997-01-29
EP0662087A1 (en) 1995-07-12
EP1415994A1 (en) 2004-05-06
WO1993024529A1 (en) 1993-12-09
CA2137377A1 (en) 1993-12-09
JP2005112863A (ja) 2005-04-28
JP2004262947A (ja) 2004-09-24
DE69333229T2 (de) 2004-08-12
EP0662087B1 (en) 2003-10-01
DE69333229D1 (de) 2003-11-06
JPH07508646A (ja) 1995-09-28
AU4406993A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
EP0662087B1 (en) Method for purifying retinal pigmented epithelium derived neurotrophic factor
US7511009B2 (en) Retinal pigmented epithelium derived neurotrophic factor
US7179621B1 (en) Pigment epithelium-derived factor: sequence of the PEDF gene
DE3880739T2 (de) Expression von menschlichem proapolipoprotein a-1.
US5411941A (en) Heterodimeric osteogenic factor
Kato et al. Multiple molecular forms of glia maturation factor
CZ287810B6 (cs) Sekvence DNA, rekombinantní molekula DNA s jejím obsahem, způsob výroby proteinu ze skupiny látek TGF-beta, farmaceutický prostředek s jeho obsahem, protilátka nebo její fragment a její použití
EP0476233B1 (en) Human MK gene and protein sequence
JP2732556B2 (ja) 生物学的に活性なｈＮＧＦ
JPH06501617A (ja) 新規な神経栄養因子
EP0220241A1 (en) PURIFIED PROTEIN HAVING ANGIOGENIC ACTIVITY AND METHODS OF PREPARING THE SAME.
US6511823B1 (en) Heparin binding neurotrophic factor gene sequence
US5461029A (en) Method of treating herpes viral infections using HBNF and MK proteins
JPH10507081A (ja) シュワン細胞の分離および培養
Li et al. Neuron-specific enolase: a neuronal survival factor in the retinal extracellular matrix?
EP0241136A2 (en) Human class 1 heparin-binding growth factor
EP0444638A2 (en) Process for the expression of human nerve growth factor in arthropoda frugiperda cells by infection with recombinant baculovirus
EP0535336A2 (en) MK protein as cell growth inhibitor
EP0535337A2 (en) Cell growth inhibiting activities of heparin binding neurite-outgrowth promoting factor
AU744514B2 (en) Matrix binding factor
JP2003061649A (ja) Ｍａｐキナーゼ活性化剤
WO1993008267A1 (en) Cell cycle controlling compositions and methods of using same
HK1111634A (en) Pigment epithelium-derived factor: characterization, genomic organization and sequence of the pedf gene

Legal Events

Date Code Title Description
EEER Examination request